ONCIN — Oncoinvent ASA Share News
0.000.00%
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Brief: Bergenbio Presents Clinical Data On Bemcentinib In Combination With Docetaxel In Patients With Previously Treated Advanced NSCLC At ASCO Annual Meeting 2022
Brief: Bergenbio Q1 Operating Loss Narrows To NOK 78.6 Million
Brief: Bergenbio Announces Launch Of Business Strategy Focused On NSCLC And COVID-19
Brief: Bergenbio Announces Complete Data Analysis Of ACCORD2 Phase II Bemcentinib
Brief: Bergenbio Names Cristina Oliva As Chief Medical Officer
Brief: BerGenBio Q4 Operating Loss At NOK 67.3 Million
Brief: Bergenbio And Oslo University Hospital Announce The AXL Inhibitor
Brief: Bergenbio Appoints Anders Tullgren As Chairman Of Board
Brief: Bergenbio Announces Licensing Of Intellectual Property
Brief: Bergenbio Q3 Oper Loss Widens To NOK 70.5 Mln
Brief: Bergenbio Receives FDA Fast Track Designation For Bemcentinib In Lung Cancer
Brief: Bergenbio Presents Pre-Clinical And Clinical Data On Bemcentinib In STK11-positive NSCLC
Brief: BerGenBio Receives FDA Fast Track Designation For Bemcentinib
Brief: Acousort Says Chairman Martin Olin Becomes CEO Of Bergenbio
Brief: Bergenbio Says Appointment Of Martin Olin As New Chief Executive Officer From 8 September 2021
Brief: Bergenbio Q2 Oper Loss Widens To NOK 92.3 Mln
Brief: Bergenbio COVID-19 Data Presented At Annual American Society For Virology
Brief: Bergenbio Presents Encouraging Combined Data For Bemcentinib From Two Phase II COVID-19 Studies
Brief: Bergenbio Presents COVID-19 Data In Late-Breaking Abstract On bemcentinib